Efficacy and safety of etoposide for maintenance therapy of small-cell lung cancer / 医学研究生学报
Journal of Medical Postgraduates
;
(12): 290-293, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-700820
ABSTRACT
Objective Small cell lung cancer(SCLC)is generally sensitive to first-line therapy,but it has poor long-term efficacy,short-term recurrence and low sensitivity of second-line therapy.The study aimed to investigate the impact of etoposide capsule for the maintenance therapy of extensive stage SCLC. Methods A retrospective analysis was made on 82 patients with extensive SCLC treated in Tumor Hospital affiliated to Zhengzhou University from January 2014 to September 2015.The patients were divided into etoposide group(n=45,oral etoposide treatment after first-line chemotherapy)and control group(n=45,regular review after first-line therapy). Comparison was conducted in progression-free survival(PFS),total survival time(OS)and adverse reactions between two groups. Results The median PFS of etoposide group was higher than that of control group(3.5months vs 2.8months,P=0.012). The one-year and two-year survival rates of etoposide group were significantly higher than those of control group(59.5% vs 43.9%, 12.6% vs 4.9%,P<0.05). The analysis of Cox proportional hazard model showed first-line therapy(RR=2.036,95%CI1.127~3.676)and BMI≥25(RR=0.598,95%CI0.359~0.997),<18(RR=4.607,95%CI2.203~9.631)were the risk factors for survival. No significant difference was found as to the risk of adverse effects be-tween two groups. Conclusion Maintenance therapy with oral eto-poside may improve progression-free-survival(PFS)in patients with extensive SCLC,which is safe and practical for maintenance therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
/
Risk factors
Language:
Chinese
Journal:
Journal of Medical Postgraduates
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS